Committee OKs Retrospective Studies, But With Caveats

FDA's Oncologic Drugs Advisory Committee agreed that retrospective studies can be used to support predictive biomarkers. The agency convened the meeting in hopes of coming away with guidance on how to assess forthcoming applications to restrict therapies to patients, using predictive biomarkers

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet